CJClaire Julian-Reynier

Claire Julian-Reynier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claire Julian-Reynier has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Décision de participer à un essai clinique en cancérologie: influence du vécu sur les attitudes

    by J. Mancini, J. Genève, F. Dalenc, D. Genre, A. Monnier, P. Kerbrat, R. Largillier, D. Serin, M. Rios, H. Roché, et al.

    L’objectif de cette étude était de comparer les attitudes théoriques par rapport à la participation ou non à un essai randomisé contrôlé (ERC) de trois groupes comparables de patientes suivies prospectivement (cancer du sein non métastatique traité par chimiothérapie standard): ayant eu une proposition de participer à un ERC (201 acceptations, 66 refus) ou pas (n = 188). Le refus de participer semble être une décision personnelle, alors que le souhait reflète davantage l’approbation de la proposition du médecin. Lors de la proposition de participation, les médecins doivent faire face à une aversion envers le procédé de randomisation et discuter abondamment des raisons et de l’importance de la randomisation ainsi que de tous les aspects de la participation à un ERC afin de transmettre aux patients toute l’information nécessaire pour prendre une décision informée. The aim of this study was to compare, theoretically, attitudes towards participating or declining to participate in a hypothetical randomized controlled trial (RCT) involving three comparable breast cancer patient groups surveyed prospectively (non-metastatic cancer treated with standard chemotherapy): some patients were invited to participate in the clinical RCT (201 acceptances, 66 refusals) and others were not (n = 188). Patients’ acceptance to participate reflected their physicians’ approval, whereas refusal was usually a personal choice. When proposing RCTs, physicians must address patients’ negative preconceptions about randomization. Physicians should thoroughly discuss the reasons for and importance of randomization as well as the other aspects of participating in clinical trials in order to provide patients with all the information they need to make informed decisions.


  • Genetics in clinical practice: general practitioners' educational priorities in European countries

    by Claire Julian-Reynier, Irma Nippert, Jean-Marc Calefato, Hilary Harris, Ulf Kristoffersson, Joerg Schmidtke, Leo Ten Kate, Elizabeth Anionwu, Caroline Benjamin, Kirsty Challen, et al.


  • Assessing educational priorities in genetics for general practitioners and specialists in five countries: factor structure of the Genetic-Educational Priorities (Gen-EP) scale

    by Jean-Marc Calefato, Irma Nippert, Hilary J. Harris, Ulf Kristoffersson, Jorg Schmidtke, Leo P. Ten Kate, Elizabeth Anionwu, Caroline Benjamin, Kirsty Challen, Anne-Marie Plass, et al.


  • Assessment of Care by Breast Cancer Patients Participating or Not Participating in a Randomized Controlled Trial: A Report With the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer

    by Claire Julian-Reynier, Jean Genève, Florence Dalenc, Dominique Genre, Alain Monnier, Pierre Kerbrat, Rémy Largillier, Daniel Serin, Maria Rios, Henri Roché, et al.

    Purpose: Cancer patients participating in randomized controlled trials (RCTs) have not been found to have better clinical outcomes than other patients. Our objective was to assess the impact of RCTs on patients' satisfaction with care. Patients and Methods: A prospective study was carried out in a cohort of women with breast cancer (N = 455) divided into those invited to participate in an RCT (201 acceptances, 66 refusals) and a comparable control group not invited to participate (n = 188). All the patients underwent the same treatment (fluorouracil, epirubicin, and cyclophosphamide 100 mg/m2 for six cycles). One and 7 months after the beginning of chemotherapy, self-administered satisfaction scores were used to compare the women's assessment of their care (Comprehensive Assessment of Satisfaction with Care validated scale). Results: At the beginning of chemotherapy, women to whom RCT had been proposed rated the doctors' availability (average ± standard deviation [SD]: RCT acceptance group, 3.60 ± 0.78; RCT refusal group, 3.68 ± 0.87; control group, 3.41 ± 0.82; P ≤ .02) and the doctors' communication (average ± SD: RCT acceptance group, 3.56 ± 0.88; RCT refusal group, 3.67 ± 0.88; control group, 3.39 ± 0.84; P ≤ .05) higher than those to whom the trial was not proposed. After the treatment, participants in the RCT felt that their doctor was more supportive (average ± SD: RCT acceptance group, 3.04 ± 0.92; control group, 2.77 ± 0.85; P = .005) and more informative about their illness and treatment (average ± SD: RCT acceptance group, 3.34 ± 0.88; control group, 3.08 ± 0.92; P = .006) than those in the control group. The general level of satisfaction was also higher in the RCT acceptance group. Conclusion: Women participating in an RCT have a more positive picture of their doctors' care than others, probably because of the structural effects of the informed consent and data collection processes.


  • Special issue of Psycho-Oncology on cancer genetic testing and psychosocial research

    by Andrea Farkas Patenaude, Claire Julian-Reynier

  • France: Genetics Education for Non-Genetics Health Care Providers

    by Claire Julian-Reynier, Sandrine Arnaud

    Objective: This paper explores the treatment of medical genetics in undergraduate medical education, specialists’ training and continuing medical education (CME) for general practitioners, specialists, nurses and midwives. Methods: We conducted a qualitative survey of websites, published or unpublished documents, telephone interviews and mailed questionnaires. Results: Genetics is a medical speciality in France, and the small number of university professors in genetics are in charge of the genetic component of medical training of all future practitioners. The study was complicated by the ongoing waves of reforms in the French health and educational systems and by the autonomy of the faculties. Specialist training and CME in genetics is heterogeneous and not organised as a priority. Conclusions: Specialist education and CME in genetics of non-geneticist health care providers needs to be adapted to the fast ongoing developments of this field of knowledge.


  • Open Access

    Patients’ characteristics and rate of Internet use to obtain cancer information

    by Julien Mancini, Catherine Noguès, Claude Adenis, Pascaline Berthet, Valérie Bonadona, Agnès Chompret, Isabelle Coupier, François Eisinger, Jean-Pierre Fricker, Marion Gauthier-Villars, et al.

    The aim of this study was to present baseline data on the access to Internet by French breast cancer patients attending genetic clinics and to examine factors affecting Internet health-related use. Twenty-four percent of participants used Internet to obtain information about the disease. This rate was higher among patients with health occupations [adjusted odds ratio (adjOR) 2.6; 95% confidence interval (CI) 1.3–5.1], the most highly educated (adjOR 2.1; 95% CI 1.1–4.0) and those under 41 years of age (adjOR 7.3; 95% CI 2.1–26.2). Almost one of every three women was dissatisfied of this source of information.


  • L’offre de tests de prédisposition génétique au cancer du sein ou de l’ovaire en France

    by Christine Sevilla, Pascale Bourret, Catherine Noguès, Jean-Paul Moatti, Hagay Sobol, le Groupe Génétique Et Cancer, Claire Julian-Reynier

    One example of the recent advances of scientific research on the human genome is the identification of two susceptibility genes to breast/ovarian cancer, BRCA1 and BRCA2, making possible the introduction in medical practices of genetic testing to detect patients with an increased risk of developing such cancers. In this context of diffusion, two surveys were carried out to appraise the activity profiles in 1998 and in 2001 of all the different participants in those new medical practices in France, physicians in charge of genetic counselling, medical centres where consultations take place and laboratories. Results show that over the period 1998-2001, few changes occurred, mainly the reduction of the average waiting time to get the result of a genetic test, the increase in the annual number of BRCA2 families identified to a level similar to the one of BRCA1 and the automation of the biological analyses without noting a considerable increase in the annual output of laboratories till 2001 however. This surprising moderate evolution must be connected to the existence of some particular external factors making the framework of the development of these new medical and biological practices and their future really uncertain. The diffusion of BRCA1/2 genetic testing has been carried out facing the traditional difficulties of any innovating activities, but also the uncertainties related to intellectual property rights on genes and the reimbursement of genetic counselling and biological testing. These uncertainties have certainly restrained the pace of change as many actors in this field have opted for a wait and see strategy bearing in mind the possible future constraints imposed to their future activity, especially if European patents on the BRCA1/2 genes are finally granted by the European patent office (EPO).